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Abstract
Background Mental health problems are common in people with substance misuse problems. However, there is a paucity of 
evidence regarding prescribing of psychotropic medications for people with comorbid mental health and substance misuse 
problems. Objective To explore the views of service users attending an addiction service on the appropriateness of psy-
chotropic medications prescribed for their co-existing mental health problems. Setting A specialist addiction service in the 
North of England. Method A phenomenological approach was adopted. Semi-structured interviews were conducted with 
twelve service users. Data were analysed using thematic framework analysis. Main outcome measure Service users’ views 
concerning the appropriateness of their prescribed psychotropic medications. Results The following themes captured service 
users’ views on the appropriateness of their medications: beneits from medicines, entitlement to medicines, and assessment 
and review. Service users mostly described beneits from their medications (including those prescribed outside guideline 
recommendations) and there was also an awareness of the adverse efects they experienced from them. It appears that people 
with substance misuse problems have a particularly strong sense of their own needs and seek to inluence prescribing deci-
sions. Service users further described varied practices regarding assessment and review of their medications with evidence 
of regular reviews while others identiied suboptimal or inadequate practices. Conclusion Most service users described 
improved functioning as a result of their prescribed psychotropic medications. Prescriptions that are inappropriate in terms 
of their usual indications may well be justiied if they assist in stabilising service users and moving them on to recovery.
Keywords Addiction service · Appropriateness · Mental Health · Psychotropic medications · Specialist addiction service · 
United Kingdom
Impacts on practice
• Addiction service users appear to have a strong attach-
ment to their psychotropic medications and a belief that 
they have a right to be prescribed whatever they feel they 
need.
• Prescriptions that are inappropriate in terms of their usual 
indications for users of specialist addiction services may 
be justiied if they provide beneits and can be used to 
move people on to recovery.
Introduction
Lexchin [1] has described appropriate prescribing as ‘try-
ing to maximise efectiveness, minimise risks and costs, 
and respecting service users’ choices [1]. Of importance in 
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judging prescribing appropriateness are what the service 
users wants or prefers as well as the scientiic rationalisa-
tion [2, 3].
Among people with substance misuse problems, their 
wider physical, psychological and social outcomes as well 
as their views may be particularly important when assessing 
the appropriateness of their medications. People with sub-
stance misuse problems often have complex circumstances 
encompassing health, social and economic problems [4, 
5], with service users attending specialist addiction clin-
ics being more likely to have higher levels of dependence, 
multi-morbidities, functional impairment, social problems 
and use of multiple medications when compared with those 
who are not help-seeking [6, 7]. These complex needs may 
inluence prescribing decisions in this population [7, 8]. For 
example, people with co-existing substance misuse prob-
lems and mental disorders may need higher doses or longer 
duration of treatment because they may have more severe 
and persistent symptoms or they may be more resistant to 
treatment [9, 10].
Most of the published research on prescribing appropri-
ateness has focused on the assessment of pharmacological 
appropriateness [3]. Examples of measures used for assess-
ing this include the medication appropriateness index (MAI) 
[11] and the prescribing appropriateness index (PAI) [12]. 
Moving beyond the medical perspective by considering ser-
vice users’ preferences and context, introduces subjectivity 
into decision-making concerning appropriateness. Barber 
et al. [3] have argued that the introduction of subjectivity 
is appropriate when making value judgments such as this.
Furthermore, given that intoxication and withdrawal 
symptoms of substances often mimic those of anxiety and 
mood disorders, an important clinical question relates to 
whether and when psychotropic medications could be used 
in treating the mental health symptoms of people with sub-
stance misuse problems [13–15]. There is inconsistent evi-
dence that psychotropic medications such as antidepressants 
and sedative/hypnotic drugs have beneicial efects on co-
existing mental disorders in this population [16–19].
It has been suggested that the service user’s perspective 
is particularly important and should be considered where 
there is a lack of adequate evidence or doubt about the best 
course of action [20, 21]. In the UK, the NHS constitution 
states that the service it provides must relect the needs and 
preferences of service users [22]. Partnership with service 
users with open communication and consideration of their 
values and choices have been promoted in UK government 
policies and clinical guidance [23, 24], with positive efects 
reported on satisfaction, medication adherence and well-
being. Additional beneits described among those with sub-
stance misuse problems include increased personal control 
and reduced drug use [25, 26]. Generally, service users want 
to be involved in decision-making concerning their treatment 
and medications [26]. However, they often report feeling 
uninvolved in decision-making [27]. A qualitative study 
that explored the experiences of service users in treatment 
for alcohol use disorders around their treatment needs and 
satisfaction while also comparing the experiences of those 
with and without co-morbid severe mental health symptoms 
(SMHS) found that those with comorbidity described a need 
for medications to relieve their psychological symptoms and 
were often dissatisied when they were left out in the deci-
sion making process (including prescribing) [27]. Although 
this study described the treatment needs of service users 
with comorbid SMHS, it was not focused on the appropriate-
ness of prescribed psychotropic medications. No previous 
study has explored the views of people attending an addic-
tion service concerning the appropriateness of psychotropic 
medications prescribed for their co-occurring mental illness. 
Consequently, this study was carried out to address this gap. 
Diagnoses of mental health illnesses and psychotropic medi-
cations were self-reported by service users.
This study was part of the irst author’s (A.O) PhD pro-
gramme. As a pharmacist, A.O has always had an interest in 
the quality of prescribing for service users, including those 
with substance misuse problems. A.O’s pharmacy training 
with emphasis on the use of medications for the manage-
ment of substance misuse problems made her initially more 
inclined to view these disorders as brain diseases. Hence, 
A.O came with a medical perspective of substance misuse 
problems when she started her doctorate programme.
Aim
To explore the perspectives of service users in a special-
ist addiction service on the appropriateness of psychotropic 
medications prescribed for their co-existing mental health 
problems. Appropriateness was explored by assessing 
service users’ views concerning the following areas: their 
need for medications, medication efectiveness, medication 
changes, assessment and review.
Ethics approval
The study was approved by the University of York’s 
Research Governance Committee and the National Research 
Ethics Service (NRES) Committee Yorkshire & The Hum-
ber. Reference 12/YH/0325.
Methods
Study design and setting
Service users’ views were explored using a phenomenologi-
cal approach. Phenomenology is based on the assumption 
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that reality is multiple and socially constructed through the 
interaction of individuals with others and the world around 
them [28]. Semi-structured qualitative interviews were car-
ried out with 14 service users who were attending the spe-
cialist addiction service. The specialist addiction service has 
been described in a previous study [7]. Briely, it is located 
in a city in the North of England and is a statutory NHS spe-
cialist service that provides a full range of psychosocial and 
pharmacotherapies for addiction problems. All interviews 
were carried out at service users’ three-month follow-up 
appointment or at their next appointment if this was more 
convenient. Interviews were carried out with a single ser-
vice user at a time due to the sensitivity of the topic and to 
maintain conidentiality [29].
Participants
Interviews were carried out with a convenience sample of 
14 service users on current prescriptions of psychotropic 
medications. Of these 14, two service users provided very 
limited information and their data were not presented. Only 
data from 12 service users were reported. Psychotropic med-
ications included in this study were antidepressants, anxio-
lytics/hypnotics, anticonvulsants, antipsychotics and mood 
stabilisers. All service users who were interviewed also took 
part in an earlier study [30] in which the appropriateness of 
opioids and psychotropic medications were assessed using 
a modiied form of the Medication Appropriateness Index 
[11]. Convenience sampling involves recruiting people who 
are available to take part in research [31], and may not be 
representative of the study population [32]. Service users 
who were still attending the specialist addiction service prior 
to their three-month follow-up appointment and who were 
on prescribed opioids and/or psychotropic medications at 
their irst assessment were contacted by telephone to deter-
mine if they could be interviewed during their follow-up 
appointment. Twenty-three service users were on these pre-
scribed medications and 20 of them were contacted by tel-
ephone to determine if they would consent to participate in 
an interview during their follow-up assessment. The remain-
ing three service users could not be contacted. Four service 
users were not interviewed because they did not attend for 
their scheduled interviews while two service users attended 
but declined interview. Therefore, a total of 14 service users 
(of 20:70%) were interviewed and data from 12 of them are 
presented (60%).
Service users who provided consent and attended the ser-
vice for their follow-up appointment were reminded of the 
study aims and encouraged to ask for clariication where 
needed. They were then given a consent form to sign before 
the interviews commenced. The service users who were 
interviewed comprised two females and 10 males. Alcohol 
was the referral substance for all but two service users who 
were referred for problems with heroin. The mean age of 
those interviewed was 48.6 years (range: 26 to 66 years) and 
the number of psychotropic medications they were being 
prescribed at their three-month assessment ranged from 1 
to 4.
Data collection
Data were collected by the irst author, A.O. All the inter-
views were conducted in a private room at the specialist 
addiction service between October 2012 and April 2013 and 
lasted on average 47 min (range: 15 to 104 min). The topic 
guide for service users was developed from the research 
questions and advice from the project advisory group. It 
covered the following areas: service users’ medical/sub-
stance use history, need for medications, efectiveness of 
medications, assessment and review, medication change and 
quality of life. The views of ex-service users who serve as 
mentors for other service users at the specialist addiction 
service were sought about the topic guide. All interviews 
were audio-recorded and transcribed verbatim.
Data analysis
Thematic framework approach was used for data analysis 
[33]. Repeated reading of the transcripts alongside listen-
ing to the audio-recordings ensured that the authors were 
familiar with the data. This was followed by a period of 
descriptive and interpretive coding facilitated by Atlas ti (v 
6.0). This inductive approach enabled a deeper understand-
ing of the data [33]. The coding framework was expanded 
as new themes emerged. Broader themes were subsequently 
generated and frequently reviewed while comparing data 
from participants that supported the themes and also look-
ing for explanations of any diferences of viewpoints within 
the data. In order to ensure anonymity and conidentiality, 
numbers rather than names were allocated to participants. 
Trustworthiness of the data was ensured through an audit 
trail kept by A.O which detailed how data were collected, 
how themes were formed and how decisions were made dur-
ing the research process. Given A.O’s initial views on sub-
stance misuse problems as brain diseases, the interpretation 
of the data was discussed in-depth with two of the authors 
(C.L and E.H), who relected on the emerging themes and 
the depth of the analysis. C. L and E.H studied criminol-
ogy and nursing respectively. D. R is a consultant addictions 
psychiatrist.
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Results
Three main themes emerged by undertaking a thematic anal-
ysis: beneits of medicines, entitlement to medicines, and 
assessment and review. Two subthemes, medication review 
and discussion with clinicians, are further described under 
assessment and review.
Beneits of medicines
This theme emerged in response to service users’ views con-
cerning the need for their medicines and efectiveness. All 
service users described their medicines in relation to the 
efect they had on their health conditions and wider life. 
Most service users thought that their medicines had led to 
some degree of improvement in their health conditions and 
functioning. Below is a description of the positive impact of 
antidepressants on a service user’s functioning:
…because a few months ago, I didn’t take them [Cit-
alopram] for a while and I just hit rock bottom again 
and then when I started back on them again, within 
a couple of weeks I was back to normal [ID 5, male, 
heroin dependency].
As well as the health impact of their medicines, service users 
also described their medicines (in particular, antidepres-
sants) as providing valuable support in their lives:
…and during a very stressful period which, my mood 
didn’t really change that much, I used it as like a 
comfort blanket or a crutch to sort of like, I’m taking 
40 mg [Citalopram] now, so I’m bound to be all right 
[ID 23, male, alcohol dependency].
Among service users who described positive efects from 
their medicines were those who reported beneits despite 
being prescribed outside the British National Formulary 
(BNF) recommendations. One elderly service user referred 
for his alcohol problems, with a 12-year history of olanzap-
ine use at a dose above the BNF recommendation for long-
standing paranoid schizophrenia, described the beneit he 
derived from his medicine:
As soon as I was put on 25 mg of Olanzapine a day, 
at night, all slight psychotic symptoms disappeared. 
And I’ve been on those tablets for a number of years 
now and I ind that they do very well for me psychiatri-
cally. I haven’t been mentally ill for something like oh 
about ten/twelve years now… thanks to the medica-
tions [ID18, male, alcohol dependency].
There was also an awareness that alcohol could have a neg-
ative impact on the efectiveness of their antidepressants. 
The service user with long-standing paranoid schizophre-
nia described above recounted periods of depression despite 
being on luoxetine and mirtazapine. He attributed this to 
continued drinking.
Another service user with a year history of zopiclone 
use for sleep problems described beneit from his zopi-
clone (the duration of zopiclone use had exceeded BNF 
recommendations):
The Zopiclone works because within ten, twenty min-
utes I’m asleep. So that does work [ID 15, male, alco-
hol dependency].
Service users further described having side efects which 
they tolerated due to the beneits they felt they obtained. 
One service user with a ive-year history of citalopram use 
for long-standing depression described sexual dysfunction 
resulting from citalopram but reported that it was neverthe-
less efective for his depression:
Citalopram’s been great. Easy to work with, you know, 
easy to take, it doesn’t make me drowsy. I can live a 
normal life on it, and I’m happy now. The only con-
traindication or side-efect I have from citalopram is 
that sometimes it prevents ejaculation. I can get to the 
point of climax but, I don’t ejaculate [ID 23, male, 
alcohol dependency].
Almost all service users who had changes made to their 
medicines described improved functioning as a result of this.
Entitlement to medicines
While describing the need for their medicines and its efec-
tiveness, service users went ahead to describe a sense of 
entitlement to being prescribed medicines:
Well my personal opinion is that I think with doctors 
these days, I think you have to tell them what’s wrong 
with you or basically tell ‘em what you need, rather 
than the sort of old school where you went to the doc-
tor and you spent a long time explaining your symp-
toms (ID 7, male, alcohol dependency).
I do appreciate that they [Zopiclone] are addictive but 
so’s smoking, so’s driving really fast, so’s doing a lot 
of other things. It’s my health and I’ve chosen to look 
after it how I want and this is how I want (ID 57, male, 
alcohol dependency).
This theme was also evident when another service user who 
had deliberately taken an overdose of his prescribed antide-
pressant (luoxetine) and sleeping tablet (zopiclone) in order 
to self-harm and had been admitted to hospital was afraid 
his zopiclone could be stopped by his GP but demonstrated 
a recognition of his right to be prescribed it:
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And the sleeper [Zopiclone], they (hospital doctors) 
won’t prescribe it to me, so now I have to go back 
to my GP and hope that he’ll prescribe me it again, 
because obvious he’s gonna know on computer that I 
took an overdose, so he might refuse me treatment so 
I’ve put meself in a predicament there to try and get me 
medication back but I know he can’t refuse it because 
he’s putting me physically in danger then (ID 27, male, 
alcohol dependency).
Assessment and review
Two subthemes were described under this category: medica-
tion review and discussion with clinicians.
Medication review
This theme came out when service users were asked about 
the assessment and review of their medicines with most ser-
vice users describing regular review of their medicines:
Yeah, I have reviews every, I think it’s every couple 
of months or every few months, to see if I’m still ok 
on the medication, so the GP knows that it’s working 
basically. I get reviews ever so often. So they can know 
that it’s doing what it’s supposed to be doing [ID 61, 
female, alcohol dependency].
It [Paroxetine] has been reviewed several times and, he 
said “I don’t want you to come of it just yet.” and it’s 
due to be reviewed, so he’s [GP] going to see me and 
review it [ID 15, male, alcohol dependency].
By contrast, there were service users who described lack of 
optimal practices regarding review of their medicines:
But what happens with GPs and practices, you just 
become a repeat prescription, and I can go for a year 
without a review when they’re supposed to be every 
two months or every three, you know, you can be left 
to sort of loat around. And I can ring the chemist up 
and say “I need another script”. And he’ll go “right, 
OK” and it’s there two days later. You don’t have to go 
see a GP. But that’s always been the case, which is not 
really about monitoring the efect of the drug, it’s more 
a case of, well you’re on it now, so just keep taking it 
[ID 23, male, alcohol dependency].
Discussion with clinicians
Service users described discussion with clinicians as impor-
tant in assessing if their medicines are ‘right’ for them. They 
described the value of talking and listening to them:
Talking to me, listening to me, asking me, you know, 
why I was feeling the way I was, was there anything 
that had triggered things of, that sort of thing [ID 35, 
female, alcohol dependency].
Another service user with a particularly strong sense of enti-
tlement to his medication (zopiclone) described how this 
process provided an opportunity for him to express his views 
on what he wants:
Oh sitting down, talking to him about sleeping tablets 
and what I want, it’s up to me really [ID 57, male, 
alcohol dependency].
On the other hand, there were service users who described 
not being listened to, and one service user reported the short 
interval in which he was prescribed a medication:
… I could do with something better for my anxiety 
but I don’t know what other medication I can get. I’m 
just taking what the doctor prescribed me. I feel like 
I could, it would be nice if they could give me some-
thing to help me relax more [mentions Temazepam 
later], you know what I mean, to calm me down but the 
doctor won’t prescribe anything for me like that [ID 5, 
male, heroin dependency].
… So I was just telling the doctor basically what my 
problems were and was prescribed Paroxetine, yeah, 
Paroxetine, I don’t think my GP probably listened 
and, yeah, listened and prescribed me a drug. I just 
went for a ive minute chat with my doctor … it was 
just I went for a quick meeting with my GP and told 
him my problems and sent away with a prescription 
[Paroxetine]. It was just, go to the doctor and of you 
go, there’s your prescription of you go [ID 7, male, 
alcohol dependency].
Discussion
This qualitative study aimed to explore service users’ 
views on the appropriateness of psychotropic medications 
prescribed for their co-existing mental health problems. 
Generally, service users described beneits from their medi-
cations (including those prescribed outside guideline rec-
ommendations) with trade-ofs between their beneits and 
adverse efects. Service users had a sense of entitlement to 
being prescribed medications and seek to direct treatment 
decisions in line with their self-perceived needs. There were 
difering practices regarding the assessment and review of 
their medications.
Most service users described beneits from their medi-
cations, including service users who had been prescribed 
medications outside guideline recommendations. It was 
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unclear whether all those prescribed outside guideline rec-
ommendations were aware of it because the interviews did 
not explore this issue due to its sensitive nature. Prescribing 
outside guideline recommendations (of-label prescribing) 
is common in psychiatry [34] due to the limited number 
of clinical trials on patients with mental health problems 
(especially those with complex needs) [35] as well as the 
non-availability of licensed medications for some psychiatric 
diagnoses [36]. Of-label prescribing may therefore be nec-
essary where there is a lack of an equally safe and efective 
licensed alternative, informed consent from the patient to 
be treated of-label, suicient evidence in the literature to 
support the use of the drug as well as suicient experience 
of using the medicine by the prescriber [36].
Best practice recommendations including dosing and 
duration recommendations are usually established in clini-
cal trials especially RCTs and where available, they serve as 
the foundation for clinical guidelines [37, 38] including the 
BNF. Where there is no evidence from clinical trials, rec-
ommendations are based to a large extent on the opinions of 
experts who have substantial experience in that area [39]. It 
may not be possible to directly extrapolate recommendations 
from guidelines on prescribing of psychotropic medications 
to people with substance misuse problems because most of 
the evidence from RCTs exclude them [40, 41]. Changes 
in the neurochemistry of the reward pathways of the brain 
secondary to chronic use of substances may also afect pre-
scribing decisions [42] including dosing. Furthermore, con-
sideration of the repercussions of relapse to substance use 
on the individual and society may well justify the need to 
sometimes prescribe outside guideline recommendations. 
Evidence from this study suggests that the appropriateness 
of prescribing is open to interpretation as some service users 
tended to view medications that improved their functioning 
as appropriate for them even when they were inappropriate 
by guideline standards.
While of-label prescribing may be clinically beneicial 
[34] for people with substance misuse problems, it also car-
ries clinical risks such as adverse efects. For instance, pre-
scribing supra-BNF doses of antipsychotics carries a greater 
risk of unwanted side efects such as extrapyramidal side 
efects, sedation, tachycardia, weight gain, postural hypo-
tension, and hyperprolactinaemia [43]. The need for high 
doses of psychotropic medications such as anxiolytics/hyp-
notics may also expose the patient to the risk of dependence. 
In addition, people with substance misuse problems may 
exceed the recommended doses of these medications with 
the potential for overdosing [44]. Although prescribers to 
achieve clinical beneit with minimal risk of harm, there 
is sometimes conlict between balancing efectiveness and 
risk [45].
Service user involvement in their own care now repre-
sents a core value in the medical profession and UK National 
Health Service (NHS) [24, 46]. The NHS constitution states 
that NHS services must relect the needs and preferences 
of service users [22]. However, there is sometimes conlict 
between physician-assessed need and what service users 
want, and how far prescribing should be determined by 
either of this remains an unresolved question [2, 45]. Ser-
vice users often have complex needs and risk issues that 
need to be taken into consideration in treatment decisions. 
Service users’ choices are challenging when people have 
substance misuse problems because they may be less than 
open about the reasons why they want medications. Given 
that service users may be at risk from medications [13, 44, 
47], prescribing decisions should be justiied, and also be 
with due precautions that may involve limit setting, monitor-
ing and behavioural rules in this population [44]. Neverthe-
less, prescribers may be under considerably greater pressure 
to respond to the self-perceived needs of substance users 
compared with other patient groups. People with substance 
misuse problems appear to have a particularly strong sense 
of their own needs and seek to make their own choices about 
their prescriptions. This sense of empowerment may well 
inluence prescribing decisions.
Furthermore, there should be efective communication 
between the prescriber and service user for the best deci-
sion to be arrived at [48, 49]. The responses of service users 
in this study highlighted the fact that many of them valued 
this two-way communication. However, there were service 
users who described inefective communication or dissat-
isfaction with their medications. This inding supports the 
results of a previous study [27] where service users with 
co-existing severe mental health symptoms and alcohol use 
disorders valued being involved in treatment decisions and 
expressed the need for control over them. Service users in 
this previous study were often dissatisied when decisions 
were made without their input. Service users usually report 
better satisfaction, medication adherence, improved well-
being, increased personal control and reduction in drug use 
when clinicians partner with them in decision-making [25, 
26]. Health care strategies and UK guidance have also high-
lighted the importance of partnering with service users [23, 
24].
It has been suggested that prescribing may be used as a 
means of terminating diicult consultations [50]. This may 
be more common in those with substance misuse problems, 
especially in time-pressured settings such as general practice 
[51]. This suggests that where service users with substance 
misuse problems do have their health conditions reviewed, 
GPs may prescribe without careful assessment and prescrip-
tions may therefore be inappropriate.
There is a growing trend to use mood-altering drugs 
including antidepressants to treat instances of human dis-
tress or emotional unhappiness [52, 53]. It is possible that 
prescribing in response to life’s challenges and problems 
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may be more common among people with substance mis-
use problems because of their high levels of vulnerability. 
Their situations are often complex with family disruptions, 
social and economic deprivation being prominent features 
[5, 54]. The lifestyle of service users usually contributes 
to these problems and may result in demoralisation, a 
sense of distress and hopelessness [44] which prescribers 
may be tempted to ‘ix’ with a pill. It is noteworthy that 
although medications are often very accessible they may 
not be the optimal solution. There is therefore the need for 
practitioners who are competent in delivering appropriate 
psychosocial therapies as protracted prescribing should 
be secondary to interventions geared to motivating people 
to make signiicant lifestyle changes. Integrated treatment 
by multidisciplinary teams with a focus on both the men-
tal health disorder and substance misuse problem using a 
combination of pharmacotherapy and psychotherapy may 
also be needed. This approach has been shown to be more 
efective for the management of this comorbidity [55, 56].
Repeat dispensing services, where repeat supply of 
medications are managed by the service user’s pharmacy 
of choice, was introduced in the NHS community phar-
macy contractual framework in 2005 in order to manage 
repeat prescriptions more eiciently [57]. Pharmacies are 
required to have appropriate governance in place for this 
service [58]. Service users who are suitable for repeat 
dispensing include those with stable therapy, long-term 
conditions, multiple therapies and those who can self-man-
age seasonal conditions [57]. This list is not exhaustive as 
other patient categories could be added based on clinical 
assessment. Repeat dispensing requires consent from the 
service user for their information to be shared between 
the dispensing and prescribing site. Recent evidence has 
shown that service users and prescribers value repeat pre-
scribing and dispensing as it has the advantage of saving 
time, is convenient and also lexible [59, 60]. Repeat pre-
scribing further reduces the workload of prescribers. How-
ever, there have also been concerns around repeat dispens-
ing in primary care with majority of respondents in the 
report by Petty [59] stating that pharmacists never checked 
the items that were needed when they were ordered on 
behalf of the service users. The views expressed by some 
service users in this study clearly suggest that repeat pre-
scribing and dispensing were not being regularly reviewed. 
Without on regular review of repeat medications, service 
users may end up being stuck on unnecessary medications 
and may become dependent medications that have such 
tendencies. Furthermore, it is also impossible to evaluate 
whether service users are still taking their medications 
with repeat prescribing. Consequently, lack of regular 
review of repeat prescriptions can lead to failure to detect 
and resolve drug-therapy problems as well as drug wast-
age [61].
Over the course of this study and her doctorate pro-
gramme, A.O’s engagement with service users, clinicians 
and the literature has broadened her views on substance 
misuse problems. She now considers substance misuse 
problems to be complex disorders involving social, psy-
chological and behavioural mechanisms.
Strengths and limitations
To the knowledge of the authors, this is the irst study to 
explore the views of service users attending a specialist 
addiction service on the appropriateness of psychotropic 
medications prescribed for their co-occurring mental 
health problems. Given that service users with substance 
misuse problems are diicult to recruit into research stud-
ies, a convenience sample of service users were inter-
viewed. Consequently, the views of females and those 
with referral substances other than alcohol were under-
represented in the interviews. Another limitation of this 
study is the fact that diagnoses and psychotropic medica-
tions were self-reported. There was no independent assess-
ment of service users’ diagnoses. Most service users who 
took part in this study were referred from sources other 
than GPs to the addiction service and GP/referral notes 
were not available. Consequently, self-report was used as 
the source of information about diagnoses and prescribed 
medications. The indings may lack transferability to ser-
vice users in other addiction services, especially given the 
changes that have occurred in substance misuse services 
in the UK. There has been an increase in the number of 
non-statutory and private sector providers of drug and 
alcohol services. Future research should involve multiple 
sites (including services run by the NHS and third sector 
organisations), to establish if the indings of this study 
are applicable. Furthermore, a single researcher collected 
study data and the researcher’s own perspectives may have 
afected interpretations that were made. However, the con-
duct, analysis and interpretation of data were overseen by 
two of the authors.
Conclusion
Service users’ views concerning the appropriateness of their 
prescribed psychotropic medications were varied with most 
service users describing improved functioning as a result of 
their medications (including of-label prescribing). It is clear 
that prescribing practices around substance misuse problems 
and comorbidities frequently deviates from current guide-
lines and it is unlikely that any guideline committee would 
sanction the sort of pharmacotherapy. This study suggests 
that some prescriptions are inappropriate in terms of their 
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usual indications but if they can be used to maintain equilib-
rium in service users’ lives while moving them on to recov-
ery then such prescribing might be justiied. Finally, this 
study points to the need for ready availability of practitioners 
who are competent in delivering appropriate psychosocial 
therapies to motivate people to making signiicant lifestyle 
changes especially in the face of protracted prescribing.
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